


## Z-VRPR-FMK TFA

<b>Cat. No.:</b>	HY-P1407
<b>Molecular Formula:</b>	C <sub>33</sub> H <sub>50</sub> F <sub>4</sub> N <sub>10</sub> O <sub>8</sub>
<b>Molecular Weight:</b>	790.81
<b>Target:</b>	MALT1; Influenza Virus
<b>Pathway:</b>	Metabolic Enzyme/Protease; NF-κB; Anti-infection
<b>Storage:</b>	Sealed storage, away from moisture
	Powder    -80°C    2 years
	-20°C    1 year

\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 1 mg/mL (1.26 mM; Need ultrasonic and warming)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.2645 mL	6.3226 mL	12.6453 mL
5 mM	---	---	---
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Z-VRPR-FMK (TFA) (VRPR), a tetrapeptide, is a selective and irreversible MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor. Z-VRPR-FMK (TFA) can protect against influenza A virus (IAV) infection<sup>[1]</sup>.

### REFERENCES

[1]. Hatcher JM, et al. Peptide-based covalent inhibitors of MALT1 paracaspase. *Bioorg Med Chem Lett.* 2019 Jun 1;29(11):1336-1339.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA